Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1978 1
1979 2
1980 2
1981 4
1985 3
1987 1
1991 2
1994 2
1995 5
1996 2
1999 2
2000 2
2004 2
2005 1
2007 1
2008 2
2009 3
2010 1
2011 2
2012 2
2013 5
2014 4
2015 3
2016 8
2017 9
2018 18
2019 11
2020 13
2021 14
2022 9
2023 7
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Targeting HIF-2 Alpha in Renal Cell Carcinoma.
Ahmed R, Ornstein MC. Ahmed R, et al. Among authors: ornstein mc. Curr Treat Options Oncol. 2023 Sep;24(9):1183-1198. doi: 10.1007/s11864-023-01106-y. Epub 2023 Jul 5. Curr Treat Options Oncol. 2023. PMID: 37403008 Review.
Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P, Rini BI, Ornstein MC. Mendiratta P, et al. Among authors: ornstein mc. Urol Oncol. 2017 Dec;35(12):687-693. doi: 10.1016/j.urolonc.2017.08.011. Epub 2017 Sep 8. Urol Oncol. 2017. PMID: 28889919 Review.
The Immunotherapy Landscape in Renal Cell Carcinoma.
Brown LC, Desai K, Zhang T, Ornstein MC. Brown LC, et al. Among authors: ornstein mc. BioDrugs. 2020 Dec;34(6):733-748. doi: 10.1007/s40259-020-00449-4. BioDrugs. 2020. PMID: 33048299 Review.
Menstrual suppression in special circumstances.
Kirkham YA, Ornstein MP, Aggarwal A, McQuillan S; CANPAGO COMMITTEE. Kirkham YA, et al. Among authors: ornstein mp. J Obstet Gynaecol Can. 2014 Oct;36(10):915-924. doi: 10.1016/S1701-2163(15)30442-4. J Obstet Gynaecol Can. 2014. PMID: 25375306 Review.
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC, Zhu J, Desai K, Kinsey E, Kao C, Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, Tafe LJ, Dayyani F, Gupta RT, McCall S, George DJ, Glenn ST, Nesline MK, George S, Zibelman M, Morrison C, Ornstein MC, Zhang T. Brown LC, et al. Among authors: ornstein mc. J Immunother Cancer. 2022 Oct;10(10):e005249. doi: 10.1136/jitc-2022-005249. J Immunother Cancer. 2022. PMID: 36252996 Free PMC article.
133 results